I came across the information about Autodesk’s venture into tissue printing in a Dec. 19, 2012 article by Kelsey Campbell-Dollaghan for Fast Company Co.Design.com (Note: Links have been removed),
Bioprinters–or 3-D printing hybrids that can print human tissue–have been around for a few years now. As the technology emerged, a single nagging question stuck out in the mind of this post-architecture school student: what’s the software of choice for a scientist modeling a human organ?
Today, an announcement from biomedical startup Organovo and software giant Autodesk goes a long way towards answering it. …
The Organovo Dec. 18, 2012 press release provides some detail about the deal,
Organovo Holdings, Inc. (OTCQX: ONVO) (“Organovo”), a creator and manufacturer of functional, three-dimensional human tissues for medical research and therapeutic applications, is working together with researchers at Autodesk, Inc., the leader in cloud-based design and engineering software, to create the first 3D design software for bioprinting.
The software, which will be used to control Organovo’s NovoGen MMX bioprinter, will represent a major step forward in usability and functionality for designing three-dimensional human tissues, and has the potential to open up bioprinting to a broader group of users.
This looks like it’s going to be a proprietary system, i.e., the software is designed for one type of hardware, Organovo’s hardware, reminiscent of the late 1990s where printers in the graphic arts field were, in some cases, were trapped into proprietary computer-to-plate printing systems. There was an open source vs. proprietary systems competition which was eventually won by open source systems.
Organovo’s press release describes the technology they’ve developed,
Organovo’s 3D bioprinting technology is used to create living human tissues that are three-dimensional, architecturally correct, and made entirely of living human cells. The resulting structures can function like native human tissues, and represent an opportunity for advancement in medical research, drug discovery and development, and in the future, surgical therapies and transplantation.
The Dec. 17, 2012 article by Kim-Mai Cutler for TechCrunch adds more technical and business detail (Note: Link removed.),
Organovo, which went public earlier this year through a small cap offering and has a market cap of $98 million, manufactures a bioprinter that can create 1 millimeter-thick tissues. Based on research out of the University of Missouri, the company’s technology creates a bio-ink from cells and deposits new cells in a layer-by-layer matrix according to a computer design.
The Dec. 18, 2012 article by Joseph Flaherty for Wired magazine offers an analysis of the business advantages for both companies (Note: Links removed.),
Autodesk, the industry leader in CAD software, has announced it is partnering with biological printer manufacturer Organovo to create 3-D design software for designing and printing living tissue.
It’s an area of interest to Autodesk, whose software runs the industrial design and architecture worlds, allowing them to expand further into new fields by helping researchers interface with new tools.
“Autodesk is an excellent fit for developing new software for 3D bioprinters,” Organovo CEO Keith Murphy says in a press release. “This partnership will lead to advances in bioprinting, including both greater flexibility and throughput internally, and the potential long-term ability for customers to design their own 3D tissues for production by Organovo.”Jeff Kowalski, senior VP/CTO at Autodesk, echoes Murphy’s sentiment. “Bioprinting has the potential to change the world,” he says. “It’s a blend of engineering, biology and 3D printing, which makes it a natural for Autodesk. I think working with Organovo to explore and evolve this emerging field will yield some fascinating and radical advances in medical research.”
While this announcement is certainly big news, we’re multiple revisions away from 3-D printing replacement body parts. Even after the technical difficulties of printing organs or even tissue for live human use are worked through, any resulting process will need to be validated through complex clinical trials and a long review by the FDA and international authorities. Still, it will be exciting to see what medical researchers and DIY biohackers will do with these tools.
Oddly, as of today (Dec. 26, 2012) Autodesk has yet to post a press release about this deal on its own website.